Top Authors

• Most frequent coverage on VRUS

• 
  A. Reza Saadat (14 followers)

  • 2007 Biotech Performance Review (Mon, Jan 21)
  • Pharma, Biotech Present Great Investment Opportunities in 2008 (Wed, Jan 9)
  • Pharmasset's Hepatitis C Drug Has A Promising Future (Fri, Oct 5)

  More by A. Reza Saadat on VRUS »
• 
  SA Editor Abbi Adest (71 followers)

  • This Week's IPOs Part II: Ocean Power Technologies, OceanFreight, Orexigen Therapeutics, Pharmasset Inc. (Mon, Apr 23)

  More by SA Editor Abbi Adest on VRUS »
• 
  TraderMark (7373 followers)

  • Sequenom's Bombshell (Thu, Apr 30)

  More by TraderMark on VRUS »

• Most followed authors on VRUS

• 
  TraderMark (7373 followers)

  • Sequenom's Bombshell (Thu, Apr 30)

  More by TraderMark on VRUS »
• 
  SA Editor Abbi Adest (71 followers)

  • This Week's IPOs Part II: Ocean Power Technologies, OceanFreight, Orexigen Therapeutics, Pharmasset Inc. (Mon, Apr 23)

  More by SA Editor Abbi Adest on VRUS »
• 
  Dan Rosenblum (29 followers)

  • Insider Buying in Biotech Land (Tue, Apr 1)

  More by Dan Rosenblum on VRUS »

• Newest authors on VRUS

• 
  Dan Rosenblum (29 followers)

  • Insider Buying in Biotech Land (Tue, Apr 1)

  More by Dan Rosenblum on VRUS »
• 
  TraderMark (7373 followers)

  • Sequenom's Bombshell (Thu, Apr 30)

  More by TraderMark on VRUS »
• 
  A. Reza Saadat (14 followers)

  • 2007 Biotech Performance Review (Mon, Jan 21)
  • Pharma, Biotech Present Great Investment Opportunities in 2008 (Wed, Jan 9)
  • Pharmasset's Hepatitis C Drug Has A Promising Future (Fri, Oct 5)

  More by A. Reza Saadat on VRUS »

• Most commented on VRUS

• 
  TraderMark (7373 followers)

  • Sequenom's Bombshell (Thu, Apr 30)

  More by TraderMark on VRUS »
• 
  A. Reza Saadat (14 followers)

  • 2007 Biotech Performance Review (Mon, Jan 21)
  • Pharma, Biotech Present Great Investment Opportunities in 2008 (Wed, Jan 9)
  • Pharmasset's Hepatitis C Drug Has A Promising Future (Fri, Oct 5)

  More by A. Reza Saadat on VRUS »
• 
  Dan Rosenblum (29 followers)

  • Insider Buying in Biotech Land (Tue, Apr 1)

  More by Dan Rosenblum on VRUS »